SAMUEL D ISALY
CIK 1055949 · last filed 2018-01-04
SAMUEL D ISALY is a corporate insider who has filed 36 SEC Form 4 insider transactions across 23 companies since 2008. The most recent filing shows the insider sold $37.7M of PIRS on Jan 4, 2018. Across all open-market trades the lifetime net is −$250.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.05B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.05B
23
36
-$250.26M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 68,759 | $13.60 | $935.1K | -$40.22M | 2 | 2018-01-04 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 1,191,000 | — | — | -$109.49M | 3 | 2017-11-27 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | 10%+ Owner | 33 | $0.08 | $3 | $0 | 1 | 2017-11-20 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 0 | — | — | -$1.44M | 2 | 2017-10-05 |
| BOLD | 10%+ Owner | 4,806,638 | $2.48 | $11.92M | -$335.2K | 1 | 2017-09-11 |
| GKOS | Director | 1,628,111 | $165.39 | $269.27M | -$89.00M | 2 | 2017-08-17 |
| KALA | 10%+ Owner | 951 | $0.67 | $641 | $14.37M | 1 | 2017-07-27 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 3,298,516 | $64.97 | $214.30M | $0 | 1 | 2017-07-26 |
| ASND | Director | 6,149,377 | $255.23 | $1.57B | $15.00M | 1 | 2017-03-28 |
| CRVS | Director | 5,379,349 | $13.39 | $72.06M | $464.3K | 3 | 2016-06-27 |
| OTONOMY, INC. (OTIC) Delisted | Director | 1,953,300 | $0.08 | $150.4K | -$17.21M | 1 | 2015-11-24 |
| Sientra, Inc. (SIEN) Delisted | 10%+ Owner | 1,988 | $0.17 | $346 | -$14.36M | 1 | 2015-10-09 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,725,790 | — | — | $8.93M | 1 | 2015-07-21 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 1,656,582 | $19.00 | $31.48M | $0 | 2 | 2014-08-11 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | 27,531 | — | — | $2.30M | 2 | 2013-01-29 |
| SUPN | 10%+ Owner | 0 | $46.61 | $0 | -$6.19M | 1 | 2012-12-19 |
| GNOM | 10%+ Owner | 730,535 | $54.46 | $39.78M | -$9.91M | 1 | 2012-07-13 |
| PCRX | 10%+ Owner | 2,546,100 | $26.49 | $67.45M | -$1.40M | 1 | 2012-02-29 |
| CCXI | 10%+ Owner | 908,509 | $13.87 | $12.60M | $0 | 1 | 2012-02-15 |
| AMRN | Director | 345,455 | $14.43 | $4.98M | -$1.72M | 1 | 2011-03-07 |
| NxStage Medical, Inc. (NXTM) Delisted | Director | 4,152,700 | — | — | -$1.67M | 2 | 2010-09-09 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 50,430 | — | — | -$282.8K | 1 | 2009-06-11 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 137,920 | $0.01 | $1.9K | $1.91M | 2 | 2008-05-23 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-04 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Sell (S) | −5,128,860 | -$37.70M | EDGAR |
| 2017-12-20 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Mixed | — | -$1.60M | EDGAR |
| 2017-11-27 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −801,000 | -$60.08M | EDGAR |
| 2017-11-20 | X4 Pharmaceuticals, Inc (ASNS) Delisted | Conv (C) | +5,606,898 | $15.00M | EDGAR |
| 2017-11-20 | Loxo Oncology, Inc. (LOXO) Delisted | Sell (S) | −810,000 | -$60.15M | EDGAR |
| 2017-10-05 | Roka BioScience, Inc. (ROKA) Delisted | Sell (S) | −604,851 | -$411.3K | EDGAR |
| 2017-10-02 | Roka BioScience, Inc. (ROKA) Delisted | Sell (S) | −1,424,028 | -$1.03M | EDGAR |
| 2017-09-11 | BOLD | Mixed | — | -$109.8K | EDGAR |
| 2017-08-17 | GKOS | Sell (S) | −975,000 | -$36.98M | EDGAR |
| 2017-07-27 | KALA | Mixed | +7,125,837 | $14.37M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.